Stock IMRN IMMURON LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Company Immuron Limited Nasdaq

Equities

IMRN

US45254U1016

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 21:30:00 07/06/2024 BST 		5-day change 1st Jan Change
2.23 USD -3.04% Intraday chart for Immuron Limited -5.51% +18.93%
06-05 Immuron Limited Appoints Jeannette Joughin as Director CI
05-31 Immuron Limited Announces Resignation of Roger Aston as Non-Executive Director CI

Business Summary

Immuron Limited is an Australia-based biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. It operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveler’s diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), IMM-529, and CampETEC.

Sales per Business

AUD in Million2022Weight2023Weight Delta
Hyperimmune Products
100.0 %
1 100.0 % 2 100.0 % +135.85%

Sales per region

AUD in Million2022Weight2023Weight Delta
Australia
64.3 %
0 26.2 % 1 64.3 % +478.05%
United States
35.6 %
1 65.5 % 1 35.6 % +28.25%
Canada
0.1 %
0 8.3 % 0 0.1 % -98.10%

Managers

Managers TitleAgeSince
Steven Lydeamore CEO
 Chief Executive Officer 56 26/06/22
Phillip Hains DFI
 Director of Finance/CFO 64 18/04/13
Joanne Casey CTO
 Chief Tech/Sci/R&D Officer 47 -
Jerry Kanellos COO
 Chief Operating Officer 61 30/06/15
Flavio Palumbo PRN
 Corporate Officer/Principal 50 31/10/22
Travis Robins PRN
 Corporate Officer/Principal - -
Reza Moussakhani PRN
 Corporate Officer/Principal - 31/08/13

Members of the board

Members of the board TitleAgeSince
Daniel Pollock BRD
 Director/Board Member 64 10/10/12
Paul Brennan CHM
 Chairman 63 15/03/22
Ravi Savarirayan BRD
 Director/Board Member 57 06/04/17

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 227,798,346 186,838,122 ( 82.02 %) 0 82.02 %

Shareholders

NameEquities%Valuation
Grandlodge Capital Pty Ltd.
2.271 %
5,178,899 2.271 % 336 318 $
Stephen Anastasiou
2.141 %
4,882,388 2.141 % 317 062 $
Russell Kay Hancock
1.316 %
3,000,000 1.316 % 194 820 $
Karma Wealth Pty Ltd.
1.119 %
2,551,665 1.119 % 165 705 $
Texas Woods Pty Ltd.
1.015 %
2,314,674 1.015 % 150 315 $
Gravcon Pty Ltd.
0.8772 %
2,000,000 0.8772 % 129 880 $
Insync Investments Pty Ltd.
0.8772 %
2,000,000 0.8772 % 129 880 $
Roger Aston
0.6668 %
1,520,376 0.6668 % 98 733 $
William David Frank Bird
0.6579 %
1,500,000 0.6579 % 97 410 $
Hallam Drainage Pty Ltd.
0.6492 %
1,480,064 0.6492 % 96 115 $
NameEquities%Valuation
HRT Financial LLC
0.4183 %
23,842 0.4183 % 57 936 $
Two Sigma Securities LLC
0.1905 %
10,860 0.1905 % 26 390 $
Stephens Consulting LLC
0.0263 %
1,500 0.0263 % 3 645 $
UBS Securities LLC
0.0189 %
1,076 0.0189 % 2 615 $
RhumbLine Advisers LP
0.0177 %
1,010 0.0177 % 2 454 $
Morgan Stanley Capital Services LLC
0.0104 %
591 0.0104 % 1 436 $
BNP Paribas Arbitrage SA
0.007018 %
400 0.007018 % 972 $

Company contact information

Immuron Ltd.

62 Lygon Street Level 3

3053, Carlton

+61 3 9824 5254

http://www.immuron.com
address Immuron Limited(IMRN)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Biopharmaceuticals

Sales per Business

Sales per region

Sector Biopharmaceuticals

1st Jan change Capi.
CSL LIMITED Stock CSL Limited
+0.82% 91.94B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
-1.32% 38.74B
BIOGEN INC. Stock Biogen Inc.
-12.88% 32.82B
UCB Stock UCB
+64.77% 26.66B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-16.31% 15.32B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-11.38% 11.65B
ALTEOGEN INC. Stock ALTEOGEN Inc.
+173.10% 10.37B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-49.84% 10.12B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.24% 9.06B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. IMC Stock
  4. IMRN Stock
  5. Company Immuron Limited
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW